Ankaferd Blood Stopper for controlling gastrointestinal bleeding due to distinct benign lesions refractory to conventional antihemorrhagic measures.

Abstract

OBJECTIVE To assess the hemostatic efficacy of the Ankaferd Blood Stopper (ABS, Ankaferd Health Products Ltd, Turkey) hemostatic agent for controlling gastrointestinal bleeding associated with various benign lesions refractory to conventional antihemorrhagic measures. METHODS The records of all patients who underwent upper and lower endoscopy procedures at the Turkiye Yuksek Ihtisas Teaching and Research Hospital (Ankara, Turkey) between April 2008 and June 2009 were reviewed. Patients in whom ABS was used as a primary or adjuvant hemostatic agent were included in the study. Rates of bleeding control and postprocedural complications were documented. RESULTS Hemostasis with no immediate complications was achieved in all patients within seconds of endoscopic application of ABS. CONCLUSIONS ABS may have a role as a primary treatment or as an adjuvant to conventional modalities used to control gastrointestinal bleeding. Prospective controlled studies are needed to help establish its efficacy and, perhaps, offer a comparison with conventional hemostatic interventions.

0204020102011201220132014201520162017
Citations per Year

143 Citations

Semantic Scholar estimates that this publication has 143 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Kurt2010AnkaferdBS, title={Ankaferd Blood Stopper for controlling gastrointestinal bleeding due to distinct benign lesions refractory to conventional antihemorrhagic measures.}, author={Mevl{\"{u}t Kurt and Ibrahim Koral Onal and Meral Akdoğan and Murat Kekilli and Mehmet Arhan and Abdurrahim Yee Sayilir and Erkin Oztaş and Ibrahim Celalettin Haznedaroğlu}, journal={Canadian journal of gastroenterology = Journal canadien de gastroenterologie}, year={2010}, volume={24 6}, pages={380-4} }